RxDoctor Payments Data

Lindsey Hernandez

Family · Bossier City, LANPI 1598482861

Payments from drug & device makers

$1,594in general payments, 2019–2025

Across 82 payments — averaging $19.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$211
  • Lilly USA, LLC$196
  • AstraZeneca$193
  • Novo Nordisk$139
  • Dexcom, Inc.$122
  • Amgen$116
  • plus $618 from 13 others

What the payments were for

  • Food & beverage$1,594100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,594 in reported general payments places this provider in the 70th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$45,328
Medicare patients
256
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide26$30,114
EliquisApixaban42$27,106
OzempicSemaglutide22$25,387
FarxigaDapagliflozin Propanediol14$7,805
Pantoprazole Sodium60$1,016
Levothyroxine Sodium128$1,002
Celecoxib18$938
SynthroidLevothyroxine Sodium27$927
Atorvastatin Calcium103$858
Rosuvastatin Calcium80$826
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine17$757
Gabapentin62$756
Losartan Potassium78$741
Metoprolol Succinate61$707
Zolpidem Tartrate123$673

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$196$30,11426 claims
PfizerEliquis$115$27,10642 claims
Novo NordiskOzempic$139$25,38722 claims
AstraZenecaFarxiga$193$7,80514 claims
AbbVieSynthroid$86$92727 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,610 family providers in Louisiana.

Other family in Bossier City

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →